Scratching an itch releases both dopamine and serotonin, but they act in different parts of the circuit. Dopamine drives the reward and urge to scratch through the brain's mesolimbic pathway. Serotonin from the brainstem and spinal cord gates itch transmission and contributes to the scratch-pleasure signal. The result is a brief relief sensation that reinforces the behavior, then often rebounds into more itching.

The question matters beyond curiosity. Chronic itch affects roughly one in five adults at some point, and the scratch-relief loop sits at the center of conditions like atopic dermatitis and psoriasis. Understanding which neurotransmitter does what helps explain why scratching feels good, why it can become compulsive, and why blocking one chemical rarely fixes the problem.

The scratch-relief circuit, step by step

An itch begins when pruriceptors, a subset of unmyelinated C-fibers in the skin, detect irritants. These neurons respond to histamine, to proteases, to cytokines like IL-31, and to a long list of other pruritogens. They carry signals to the dorsal horn of the spinal cord, where a dedicated population of itch-selective neurons relays them upward.

The signal reaches the brain's somatosensory cortex, which registers the location and intensity, and the insular cortex, which produces the conscious feeling of "I need to scratch." That feeling alone is not enough to explain behavior. The urge has a motivational component, and that is where dopamine enters.

Scratching activates low-threshold mechanoreceptors in the skin. These touch fibers inhibit itch-selective neurons in the spinal cord through local interneurons, a mechanism called gate control. This is the fast part of relief, and it happens within seconds. The spinal gate suppresses itch signaling while the scratch is happening, which is why a hard scratch can temporarily silence even an intense itch.

The slow part is chemical. Touch and scratch signals also reach the midbrain's ventral tegmental area, the origin of the mesolimbic dopamine pathway. Dopamine rises in the nucleus accumbens, and that signal encodes the scratch as rewarding. A landmark study in mice by Binhui Zhao and colleagues, published in Neuron in 2024, showed that a specific serotonin-to-dopamine pathway from the brainstem raphe nuclei to the ventral tegmental area drives the urge to scratch. This finding directly ties the two systems together rather than setting them at odds.

So the answer to the headline question is not either-or. Dopamine and serotonin cooperate. Serotonin helps generate the urge and gates spinal itch, while dopamine stamps the scratch with reward value.

Quantifying the pleasure and the dose

There is no clean human threshold in milligrams or nanograms for scratch pleasure. What researchers have measured is behavioral, not absolute. In animal models, blocking dopamine D1 or D2 receptors in the nucleus accumbens reduces scratching bouts, which supports a reward role. In humans, imaging and pharmacological studies point the same direction, though the numbers are less tidy.

Serotonin complicates the picture because it has opposite effects depending on where it acts. In the spinal cord, serotonin from descending pathways can suppress itch. In the brain, serotonin activity in the raphe can drive the urge. Drugs that raise brain serotonin, such as SSRIs, occasionally trigger itching as a side effect even as they treat itch in some conditions. This split behavior is the main reason simple "block serotonin" strategies fail.

Dopamine's contribution is similarly dose-dependent rather than absolute. A boring scratch generates a small reward signal. A vigorous scratch generates a larger one. That is why people scratch harder than necessary. The reinforcement is not proportional to itch relief alone. It tracks the scratch itself, which means the reward can persist after the itch signal has faded.

One useful comparison is the latency of relief. Gate-control suppression is nearly instantaneous, on the order of tens of milliseconds. The dopamine reward builds over seconds. Serotonin's role in generating the urge operates over minutes. These are different timescales, which is why the full loop can take several minutes to resolve.

Comparison of the two neurotransmitter roles

Feature Dopamine Serotonin
Main location of action Mesolimbic reward pathway Brainstem raphe and spinal cord
Primary role in scratching Reward and reinforcement Urge generation and itch gating
Effect on scratching behavior Increases bouts when enhanced Drives urge centrally, suppresses itch spinally
Timescale Seconds Minutes
Effect of blocking Reduces scratch bouts in animal models Mixed; can worsen or improve itch
Clinical relevance Reward loop in compulsive scratching SSRI-induced itch as a known side effect

The table shows why neither neurotransmitter can be labeled "the" itch chemical. They occupy different nodes of the same loop.

Timeline of a single scratch episode

Stage Time after itch onset What happens
Detection 0 ms Pruriceptors in skin fire
Spinal relay Tens of milliseconds Dorsal horn itch neurons activate
Conscious awareness Roughly 100 to 200 ms Insular and somatosensory cortex register itch
Gate-control suppression Within seconds Touch fibers inhibit spinal itch neurons
Dopamine reward Several seconds Ventral tegmental area to nucleus accumbens signal
Serotonin urge signal Seconds to minutes Raphe to ventral tegmental area pathway engages
Rebound Minutes to hours Itch often returns, sometimes stronger

The rebound stage is the most clinically important row. Scratching relieves itch briefly but frequently worsens it afterward. That pattern is the same one that sustains compulsive skin-picking behaviors.

The scratch-itch cycle and why it persists

The reason scratching can make itching worse is not fully settled. Several mechanisms are supported. Repeated scratching damages the skin barrier. Barrier damage lets irritants and bacterial products reach pruriceptors more easily. Mechanically, scratching also sensitizes nerve endings in the area, lowering the threshold required to trigger the next itch signal.

Serotonin appears in the rebound story too. When scratch activates serotonin neurons, the same signal that drives the urge can contribute to enhanced itch sensitivity through downstream receptors. Blocking certain serotonin receptor subtypes reduces scratching in some experimental models. This is partly why antihistamines, which target histamine and not serotonin, fail for many chronic itches.

The dopamine side explains why the behavior is hard to stop. A reward signal after a scratch teaches the brain that scratching works. Over time, the association strengthens, and scratching can become a habit even when the itch signal is mild. People with chronic itch frequently describe scratching as automatic, not deliberate. That description matches a reward-driven learned behavior rather than a simple response to sensation.

Here is the counterintuitive point. Reducing the itch itself is not always enough to stop the scratching. If the reward association is strong, the behavior can persist after the itch is gone. This is why behavioral treatments, such as habit-reversal techniques, often succeed where itch-suppressing drugs alone do not.

Red-flag warning signs

Scratching that leaves open sores, or skin that feels hard and thickened Itch that persists for more than six weeks without a clear cause New itch that appears without a rash or with weight loss, fevers, or night sweats Itch that interferes with sleep on most nights Itch accompanied by jaundice, or by numbness or changes in sensation Itch that worsens with heat or bathing and spreads rapidly

These signs warrant a medical evaluation rather than a self-treatment approach. Several systemic conditions can present with chronic itch before other symptoms appear.

Common misconceptions, corrected

The first misconception is that scratching is purely a mechanical reflex. The reflex exists, but the rewarding nature of scratching comes from the brain, not the spinal cord. An itch that cannot be reached by hand, or a scratch that cannot relieve it, still activates the urge system.

The second is that dopamine is only about pleasure. Dopamine also encodes motivation and salience, which is why an itch can feel like a task that must be completed. The relief signal is part of a goal-directed system.

The third is that serotonin is calming and therefore anti-itch. Serotonin is a genuine itch-modulating transmitter, but it can be pro-itch in the brain and anti-itch in the spinal cord. General statements about serotonin and itching are usually wrong in at least one context.

The fourth is that scratching damages the skin only if it is hard or prolonged. Even light scratching can worsen barrier damage over time, especially in people with dry or inflamed skin.

The fifth is that no treatment exists beyond willpower. Habit reversal, barrier repair, and targeted therapies are all clinically used, and they work for many people.

Practical steps that respect the neurochemistry

The actions below are not medical advice for a specific person. They reflect general strategies that align with what the mechanisms suggest.

Interrupt the scratch before the reward lands. The reward builds over seconds, so a substitution done quickly is more likely to break the association. Use cooling or pressure instead of scratching. Rubbing, tapping, or applying something cold engages touch fibers without the same reward signature. Keep skin hydrated and the barrier intact, since dry skin lowers the itch threshold. Treat the underlying condition, such as eczema or psoriasis, rather than only the sensation. Practice habit reversal, which involves noticing the urge and doing a competing action such as clenching the hands for 30 seconds. Ask a clinician about triggers, including medications that can cause itch.

The thresholds matter. An itch lasting more than six weeks is considered chronic and should be evaluated. Itch that disrupts sleep for more than a few nights in a row is a reason to seek care earlier rather than later. These are practical thresholds, not hard rules.

What remains uncertain

The science here is more stable than the headlines suggest, but it has real limits. Much of the strongest evidence comes from animal research. The Zhao study in Neuron in 2024 is strong mechanistic work, but mouse circuits are not human circuits, and the human data are mostly imaging and pharmacological, not direct measurements of synaptic dopamine and serotonin during scratching.

The human neuroscience cannot measure the exact amount of dopamine or serotonin released during a single scratch. No clinically available test reports scratch-related neurotransmitter levels. Claims with specific nanogram figures should be treated with suspicion. What is established is the direction of the effects and the roles of the pathways, not a precise dose response.

There is also the question of individual variation. People differ in receptor density, in skin barrier function, and in their psychological relationship to scratching. The same pathway can produce different behavior in different people. This is not vague hedging. It is a real limit of what population-level findings can predict about one person.

One more caveat concerns treatment. Drugs that act on dopamine or serotonin are not used as itch treatments in routine practice for most patients, and they carry their own risks. The mechanism does not translate into a simple prescription. The role of dopamine and serotonin in itch is best understood as an explanation for why the behavior persists, not as a target for self-treatment.

Putting it together

Scratching an itch releases both dopamine and serotonin. Dopamine carries the reward signal that reinforces scratching. Serotonin helps generate the urge and modulates itch within the spinal cord and brainstem. The two systems talk to each other, and the pleasure of a good scratch is the output of that conversation, not a single chemical.

The practical takeaway is that stopping scratching requires interrupting a loop, not just silencing a sensation. The fast relief from gate control lasts seconds. The slower reward signal is what makes the behavior stick. Anyone trying to break the habit is fighting both timescales, which is why a combination of barrier care, habit reversal, and treatment of the underlying cause works better than any single step.